AI tools are showing up everywhere in medicine right now — in our inboxes, in meetings, and quietly in the background as we prepare talks or look up unfamiliar territory. Many of us are experimenting with them in real time, often between consults or after a busy clinic day, trying to figure out what they’re actually good at and how to use them without creating extra work. One place where AI can be genuinely helpful is in orienting yourself to a clinical question — especially

There are days in Transfusion Medicine when the most interesting teaching moments arrive quietly — between phone calls, in the apheresis unit hallway, or as someone leans back in a rolling chair and says, “Okay, but why can’t we just do a depletion exchange here?” Today it came up while troubleshooting an inpatient red cell exchange on a Sickle Cell patient who was a lot sicker than he’d been two weeks earlier. One person suggested adding a depletion phase to improve the effi

Introduction: The Problem With the "Second Brain" Metaphor Artificial intelligence in pathology and laboratory medicine is often marketed with an irresistible promise: a second brain that will spot what humans miss, automate the tedious parts of practice, and bring order to the overwhelming volume of data moving through modern health systems. It’s a compelling metaphor—but also a deeply misleading one. The truth is simpler and far more useful: most AI tools in lab medicine to

I’ve been thinking a lot about attribution bias lately — the reflex to explain someone’s behavior by pointing to their character instead of their circumstances. In medicine, this isn’t just a cognitive shortcut. It’s one of our favorite misdiagnoses, and it often shows up in the form of a single, damning label: the difficult patient. Two encounters from my own practice keep coming back to me. 1. “The Meanest Person I’ve Ever Met.” That was the handoff. The wife was “the meane

Two different patients. Two plasma exchange treatments. Two nurses asking me, gently and matter-of-factly, the same question: “Do you want to chase with some plasma?” Before becoming an attending, I had never heard the phrase. It wasn’t part of residency, fellowship, ASFA courses, or any protocol I’d ever followed. It certainly isn’t in textbooks. The first time someone asked me, I wondered whether this was a regional term or a long-standing tradition I’d somehow missed. What

For years, transfusion-associated circulatory overload (TACO) has been framed as a purely hemodynamic problem — a case of too much blood, too fast.  But hemovigilance data are challenging that simplicity. A growing body of work suggests that in a significant subset of patients, TACO runs hot. Yes, fever. Not chills from contamination, not cytokine-release fever from a leukocyte-rich product, but true fever within hours of transfusion — sometimes the only obvious clue that som

A patient was admitted with a congestive heart failure exacerbation. Their hemoglobin was drifting downward — nothing dramatic, but enough to warrant a type and screen. The result wasn’t surprising: a known warm autoantibody. What was  surprising was the note that popped up beside it — “Requires washed RBCs.” We looked into it. The patient’s IgA level was reported as < 5 mg/dL on two separate occasions — a true, complete selective IgA deficiency. No history of anaphylactic re

Two weeks after a massive transfusion protocol for hemorrhagic shock, one of our patients developed profound thrombocytopenia — counts dropping to single digits despite transfusions. Each additional platelet unit seemed to make things worse, not better. Within days, she developed intra-abdominal bleeding that required surgical exploration and an open abdomen. When the post-transfusion purpura (PTP) panel came back, it revealed an alloantibody against HPA-1b — an uncommon find

When the phone rings mid-transfusion and the words “the patient is hypotensive”  hit your ears, there’s a short list of life-threatening reactions you can’t afford to miss. Four share a similar opening act — fever, hypotension, and sometimes respiratory distress. The fifth looks different but can end the same way if unrecognized. Here’s how to triage the call, fast. 1️⃣ Anaphylaxis Clue:  Sudden hypotension, respiratory distress, flushing, or urticaria — often within minutes

Every so often a case comes along that refuses to fit into our tidy categories. An adult male presented to the emergency department with profound weakness and striking jaundice. His hemoglobin was 3.7 g/dL, yet he was mentating normally and his lactate was within range — clear evidence of physiologic compensation. The chemistry panel featured a total bilirubin >70 mg/dL, direct fraction ≈ 40 mg/dL, with biliary dilation on CT abdomen/pelvis. On the hematology side, LDH was el

The patient was a premature infant, six weeks old and just 2.5 kilograms, already on ECMO for primary cardiopulmonary failure. Sepsis developed secondarily, and the critical-care team requested plasmapheresis for a presumed cytokine storm — a Category III indication  under the current ASFA guidelines. On paper, the rationale made sense. But when I calculated the total blood volume — only 250 mL  (≈ 100 mL/kg for a premature infant) — it was immediately clear this baby was too

The antibody screen looked straightforward at first glance — an O positive patient with apparent anti-D reactivity in plasma. But the autocontrol was positive, and the eluate was a panagglutinin. Those two results change the entire story. Working the Differential When a D-positive patient’s plasma reacts like anti-D, the immediate differentials are familiar: Partial D variant (missing epitope exposure) Passive anti-D (recent RhIg or IVIG) Autoantibody with apparent Rh specifi

1 | Finding the rhythm of replacement When people talk about plasma exchange, they usually focus on what  to replace. Less often...

1 | A brief historical arc In the early years of therapeutic plasma exchange (TPE), replacement was simple: plasma when coagulation...

The Overlooked Half of the Exchange When we talk about plasma exchange, most of the conversation centers on what we’re removing —...

This morning on the apheresis service, I saw a familiar face — one of our regular outpatients. He’s four weeks out from a total knee...

The other day, I asked an AI model about the Diego blood group system. It gave me a slick, confident answer — beautifully formatted,...

I’ve been out of training just long enough to start thinking about the long term. Over the years, I’ve sat through countless wellness...

In Part Two, we followed the fork in the road: cellular and tissue-based products that meet all four criteria in 21 CFR 1271.10(a) can...

In Part One, we mapped out how laws and regulations interact, how the FDA is structured, and why blood is both a drug and a biologic. Now...